EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Intravenous intralipid 10% vs. 20%, hyperlipidemia, and increase in lipoprotein X in humans


, : Intravenous intralipid 10% vs. 20%, hyperlipidemia, and increase in lipoprotein X in humans. Nutrition 8(3): 155-160

To clarify mechanisms of hyperlipidaemia caused by infusion of Intralipid 10%, lipoprotein metabolism during intravenous Intralipid 10 and Intralipid 20% (which contains half the amount of egg yolk lecithin for the same content of triacylglycerol as Intralipid 10%) was compared. 10 patients (7 men, 3 women, 56.6+or-8.8 years old) receiving Intralipid 10% 20 ml/kg daily and 10 (8 men, 2 women; 52.8+or-15.1 years old) receiving Intralipid 20% 10 ml/kg daily were fed exclusively by total parenteral nutrition (TPN) providing amino acid 1.1 g and 30 kcal/kg daily for 4-6 weeks. Intravenous Intralipid 10% caused a marked increase in low-density lipoprotein (LDL), and increases in phospholipid and cholesterol, especially free cholesterol. The progressive increase in lipoprotein X (LpX) was in proportion with that of LDL or total lipid, whereas no increase in lipids, LDL, or LpX was observed during intravenous Intralipid 20%. A significant increase in apolipoproteins CIII and E with Intralipid 10% also caused a rise in LpX. With Intralipid 20%, however, alterations in apolipoproteins were not observed. Lecithin:cholesterol acyltransferase (LCAT) activity was significantly elevated with Intralipid 10 but not 20%. Disappearance of LpX after cessation of Intralipid 10% was relatively rapid, and the half-life was 24-60 h. From the findings, hyperlipidaemia with Intralipid 10% was caused almost exclusively by the increase in LpX. The excess lecithin may be responsible for the formation of an increase in LpX. It was observed that Intralipid 20% could be safely used without inducing hyperlipidaemia.


Accession: 002416304

PMID: 1525430

Submit PDF Full Text: Here


Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:
Close
Close

Related references

Tenenbaum D.; Gambert P.; D'athis P.; Lallemant C.; Nivelon J L., 1986: Intravenous fat emulsion intralipid induces increase of lipoprotein lipase activity in term newborns. Pediatric Research 20(4 PART 2): 250A

Fellows I.W.; Bennett T.; Macdonald I.A., 1989: The metabolic and cardiovascular effects of intravenous infusion of glucose or intralipid in normal humans. This study was performed to determine whether the administration of intravenous fluids, isosmolar with plasma, activated the sympathetic nervous system, thereby causing changes in cardiovascular variables. On four separate occasions, six young, he...

Taskinen, M.R.; Nikkilä, E.A.; Kuusi, T.; Tulikoura, I., 1983: Changes of high density lipoprotein subfraction concentration and composition by intralipid in vivo and by lipolysis of intralipid in vitro. Serum lipoproteins were measured during a single infusion of intralipid and during parenteral nutrition with intralipid and glucose. Postheparin plasma lipolytic enzymes and plasma LCAT activity were assayed before and after the parenteral nutriti...

Rössner, S., 1973: The intravenous fat tolerance test with intralipid in various types of hyperlipidaemias and comparison between metabolism of intralipid and VLDL. Advances in Experimental Medicine and Biology 38: 69-85

Hajri, T.; Férézou, J.; Lutton, C., 1990: Effects of intravenous infusions of commercial fat emulsions (Intralipid 10 or 20%) on rat plasma lipoproteins: phospholipids in excess are the main precursors of lipoprotein-X-like particles. Like most commercial parenteral emulsions, Intralipid contains the same amount of phospholipids (12 mg/ml) to stabilize 100 or 200 mg of soybean oil (10 or 20% formula, respectively). By centrifugation, 10 or 20% Intralipid was separated into a su...

Hajri, T.; Ferezou, J.; Lutton, C., 1990: Effects of intravenous infusions of commercial fat emulsions (Intralipid 10 or 20%) on rat plasma lipoproteins: phospholipids in excess are the main precursors of lipoprotein-X-like particles. Like most commercial parenteral emulsions, IntralipidA® contains the same amount of phospholipids (12 mg/ml) to stabilize 100 or 200 mg of soybean oil (10 or 20% formula, respectively). By centrifugation, 10 or 20% Intralipid was separated into a...

Tashiro, T.; Mashima, Y.; Yamamori, H.; Horibe, K.; Nishizawa, M.; Sanada, M.; Okui, K., 1991: Increased lipoprotein X causes hyperlipidemia during intravenous administration of 10% fat emulsion in man. To clarify the mechanisms of hyperlipidaemia during intravenous Intralipid 10%, lipoprotein profiles including lipoprotein X were studied in 13 patients receiving fat 2.0 g kg body weight -1 day-1 by Intralipid 10% over a period of 8 weeks. All pa...

Hajri T.; Ferezou J.; Lutton C., 1990: Effects of intravenous infusions of commercial fat emulsions intralipid 10 or 20 percent on rat plasma lipoproteins phospholipids in excess are the main precursors of lipoprotein x like particles. Like most commercial parenteral emulsions, Intralipid contains the same amount of phospholipids (12 mg/ml) to stabilize 100 or 200 mg of soybean oil (10 or 20% formula, respectively). By centrifugation, 10 or 20% Intralipid was separated into a su...

Tsukamoto Y.; Kokubo T.; Tamura K.; Hiki Y.; Kobayashi Y., 1991: Lack of compensatory increase in high density lipoprotein hyperlipidemia due to lipoid nephrosis. Journal of the American Society of Nephrology 2(3): 275

Föger, B.; Tröbinger, G.; Ritsch, A.; Lechleitner, M.; Hopferwieser, T.; Menzel, H.J.; Utermann, G.; Pfeiffer, K.P.; Patsch, J.R., 1995: Treatment of primary mixed hyperlipidemia with etophylline clofibrate: effects on lipoprotein-modifying enzymes, postprandial lipoprotein metabolism, and lipoprotein distribution and composition. In 17 patients with primary mixed hyperlipidemia we studied levels and composition of lipoproteins in fasting plasma, lipoprotein-modifying enzymes, and postprandial lipoprotein metabolism after an oral fat-tolerance test supplemented with vitamin...